H101 Combined With Camrelizumab for Recurrent Cervical Cancer (NCT05234905) | Clinical Trial Compass
UnknownPhase 2
H101 Combined With Camrelizumab for Recurrent Cervical Cancer
China55 participantsStarted 2022-03
Plain-language summary
There is no standard treatment for recurrent cervical cancer that progresses or persists after first-line treatment. The objective response rate of anti-PD-1 antibody treatment is about 15%. The purpose of this study was to evaluate whether the regimen could improve the objective response rate by intratumoral injection of oncolytic virus(recombinant human adenovirus type 5 injection, H101) combined with anti-PD-1 antibody(camrelizumab).
Who can participate
Age range18 Years – 80 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participants voluntarily participated in this study and signed the informed consent;
✓. Participants with incurable recurrence after first-line treatment or participants with incurable recurrence within the irradiation field;
✓. At least one lesion that meets RICIST 1.1 criteria can be evaluated and can be injected intratumorally;
✓. ECOG score 0-2 points;
✓. Expected survival \> 3 months;
✓. Women of childbearing age must undergo a pregnancy test (serum or urine) before enrollment, and the result is negative, and they are willing to use appropriate methods of contraception during the trial;
Exclusion criteria
✕. There is an infection at the intended injection site;